Xcout Intel
Omnix Medical competitors & alternatives
The 12 closest competitors and alternatives to Omnix Medical among biotech companies — ranked by similarity to what Omnix Medical actually does, not by market-cap band.
Subscribe to see Omnix Medical’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Omnix Medical
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Omnix Medical at a glance
Omnix Medical is a biotech company headquartered in Israel, founded in 2015. Its most recent funding round raised $11.7M in January 2021.
Omnix Medical funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $11.7M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Omnix Medical competitors
Ranked by semantic similarity — how close each company is to Omnix Medical by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Bugworks Research Inc. is a clinical-stage biopharmaceutical company headquartered in Bangalore, India, developing novel therapeutics to combat antimicrobial resistance.
Biotechnology
BioVersys AG is an award-winning, privately-owned Swiss pharmaceutical and biotech company headquartered in Basel, Switzerland, focused on the research and development of antibacterial treatments for drug-resistant bacterial infections.
Biotechnology
Maxwell Biosciences, Inc. is a biotechnology company based in Austin, Texas. It develops biomimetic, peptide-inspired anti-infective drugs designed to act as a synthetic immune system.
Biotechnology
Qpex Biopharma, Inc. is a biopharmaceutical company located in San Diego, California, specializing in infectious disease solutions as part of the Shionogi Group.
Biotechnology
TXN Systems AB is a healthcare company developing an innovative antibiotic regimen targeted at treating complicated urinary tract infections caused by antibiotic-resistant bacteria.
Biotechnology
AMR Bio is a clinical-stage biotechnology company headquartered in London, United Kingdom, focused on infection prevention and antimicrobial resistance. The company is dedicated to developing novel anti-infectives, including its Phase 3-ready, first-in-class topical antimicrobial candidate XF-73.
Biotechnology
Obulytix is a biotechnology startup founded in 2023 and headquartered in Ghent, Belgium, focused on advancing antimicrobial innovation and building the future of antibiotics.
Biotechnology
Alopexx, Inc. is a U.S. biotechnology company developing broad-spectrum anti-infective vaccines and antibody-based therapies. Its programs target PNAG, a surface polysaccharide found on many bacterial and fungal pathogens, for potential treatment or prevention of serious infections.
Biotechnology
Oragenics, Inc. is a biotechnology development-stage company incorporated in Florida in 1996 and headquartered in Lakewood Ranch, Florida. It is dedicated to fighting infectious diseases, including coronaviruses and multidrug-resistant pathogens.
Life Sciences
Omniose is an early-stage biotechnology and life sciences company headquartered in Saint Louis, Missouri. The firm develops polysaccharide conjugate vaccines against serious bacterial threats using its proprietary technology.
Similar biotech company
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Omnix Medical and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Omnix Medicaland every competitor above — in one live dashboard.
Subscribe to Xcout Intel →